Clinician Guide to Angiogenesis

Circulation

Volumn 108, Issue 21, 2003, Pages 2613-2618

  Fam, Neil P ^a   Verma, Subodh ^b   Kutryk, Michael ^a   Stewart, Duncan J ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOTENSIN; ANGIOTENSIN I; BASIC FIBROBLAST GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROTEIN; LIVER ENZYME; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2;

ANGINA PECTORIS; ANGIOGENESIS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY; CORONARY ARTERY DISEASE; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; ENDOTHELIUM CELL; ENZYME BLOOD LEVEL; FEVER; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOTENSION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; QUALITY OF LIFE; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; STABLE ANGINA PECTORIS; STEM CELL; TREATMENT OUTCOME; TUMOR GROWTH; VASCULAR ENDOTHELIUM; VIRAL GENE THERAPY;

ANGIOPOIETINS; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; STEM CELL TRANSPLANTATION; VASCULAR ENDOTHELIAL GROWTH FACTORS; VASODILATION;

EID: 0344844433     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000102939.04279.75     Document Type: Review

References (26)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285: 1182-1186.
2. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275: 965-967.
3. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
4. Sasayama S, Fujita M. Recent insights into coronary collateral circulation. Circulation. 1992;85:1197-1204.
5. Yancopoulos G, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
6. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277: 48-50.
7. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res. 2001;49:659-670.
8. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. An expert panel summary. Circulation. 2000;102:e73-e86.
9. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation. 2002;105:2133-2135.
10. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274(3 Pt 2):HI054-HI058.
11. Babaei S, Stewart DJ. Overexpression of endothelial NO synthase induces angiogenesis in a co-culture model. Cardiovasc Res. 2002; 55:190-200.
12. Matsunaga T, Weihrauch DW, Moniz MC, et al. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation. 2002;105: 2185-2191.
13. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106:913-919.
14. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002;136:54-71.
15. Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation. 2002;105:735-741.
16. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105:3017-3024.
17. Fabre JE, Rivard A, Magner M, et al. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation. 1999;99:3043-3049.
18. Kleiman NS, Califf RM. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology. J Am Coll Cardiol. 2000;36: 310-325.
19. Henry TD, Annex BH, Azrin MA, et al. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 1999;100(suppl I):I-476. Abstract.
20. Grines CL, Watkins MW, Helmer G, et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002;105:1291-1297.
21. GVVEGF121.10) delivered through minimally invasive surgery versus maximum medical treatment in patients with severe angina, advanced coronary artery disease, and no options for revascularization. Circulation. 2002;106:2986-a. Abstract.
22. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002;105: 2012-2018.
23. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434-438.
24. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913-1918.
25. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002;106:3009-3017.
26. Szmitko PE, Fedak PWM, Weisel RD, et al. Endothelial progenitor cells: new hope for a broken heart. Circulation. 2003;107: 3093-3100.